Introduction {#sec1}
============

A lot of medical studies involve the clinical influence of comorbidity factors, which often explain the probability of readmission, mortality \[[@cit0001]\] or other medical relations \[[@cit0002]\]. Measures of the overall medical condition of patients seem to be an interesting topic from the point of view of both patients and medical service providers. The literature review on the potential applications of comorbidity measures shows their great impact on many important aspects of healthcare analysis. Charlson *et al.* \[[@cit0003]\] introduced a comorbidity index (CCI). The CCI has been developed mainly by Deyo *et al*. \[[@cit0004]\], Romano *et al*. \[[@cit0005]\] and Elixhauser *et al*. \[[@cit0006]\]. Based on Charlson's concept, with some additional assumptions and improvements in methodology related to 30 groups of comorbid categories and diagnosis-related groups (DRG), Elixhauser *et al.* used comorbidities to predict in-hospital mortality \[[@cit0006]\], length of stay at hospitals, and medical expenditure. A systematic review confirmed that Elixhauser's approach had a good performance in predicting in-hospital death \[[@cit0007]\]. It was shown \[[@cit0008]\] that predicting mortality considering the prior 1-year history of patient's hospitalisations for defining comorbidity yields better results than depending solely on diagnoses from the index hospitalisation.

Risk adjustment is a crucial procedure in treatment quality assessment. We wanted to create a measure that would be based on administrative data only and would enable us to compare the burdens of patients hospitalised for different reasons.

It is clear that the Charlson/Elixhauser approach to comorbidity does not provide such a possibility -- cardiac and allergological patients with the same comorbidities would be assigned the same death probability despite the fact that they are obviously different. Moreover, it was shown \[[@cit0006]\] that for varying primary diagnoses, comorbidities have different effects. For that reason, we introduced Homogeneous Groups -- separate models for groups of primary diagnoses. That way, in our risk-adjustment method, we took the primary diagnosis into account in the estimation of both baseline risk and effect of each comorbidity by estimating them separately for each group.

There are more complex risk-adjustment methods with results better than comorbidity-only models. Escobar *et al.* in \[[@cit0009]\] achieved a C-statistic of 0.88 by taking into account the laboratory results and admission type. Such an approach has the disadvantage of being inapplicable to administrative databases that do not include such information.

This study aimed to measure the patient's burden based on administrative data only, using Elixhauser's approach and to validate the estimation power of models built on homogeneous groups with respect to the main reason for hospitalization.

Material and methods {#sec2}
====================

Homogeneous groups {#sec2.1}
------------------

Our models were created for the heterogeneous group of all admissions and for 21 Homogeneous Groups (HGs). Each HG was defined by a chapter of the International Classification of Diseases, revision 10 (ICD10) published by WHO. Each admission was classified as belonging to a certain HG if the main reason for hospitalisation was included in a corresponding chapter of ICD10.

Approach {#sec2.2}
--------

Elixhauser's methodology is based on modelling different explanatory variables such as mortality or length of stay using comorbid variables (CVs) referring to 1-year of medical history. Deyo *et al.* \[[@cit0004]\] selected 30 comorbid variables defined by ICD-9-CM codes. Our methodology followed Elixhauser's approach with only slight changes in definitions of input and output variables. As our models were based on administrative data, we needed to map the ICD10 codes (used in Polish healthcare) onto CVs. Our grouping followed those \[[@cit0010]\].

Diagnosis-related groups and comorbid variables {#sec2.3}
-----------------------------------------------

To avoid taking into account the main reason for hospitalisation, Elixhauser introduced Diagnosis Related Groups (DRGs) as broader groups of diseases used to screen comorbid variables (CVs). Every CV had its own DRG. For a given CV, its DRG was defined as all morbid conditions for which the diseases might be directly related to the main reason for hospitalisation and not only a coexistent one. In our approach, DRGs were defined as all ICD10 codes that referred to CV and Homogeneous Groups (HG) closely related to that particular CV. HGs related to CVs as well as definitions of CVs are included in [Appendix B](#app02){ref-type="app"}. It is worth noting that the presence of DRGs is one of the most prominent differences between \[[@cit0006]\], \[[@cit0003]\] or \[[@cit0011]\] approaches.

For every hospitalisation, we determined a value for each of 31 Comorbid Variables as follows:

-   If the main reason for hospitalisation fell into the DRG of that CV, it was always set to 0.

-   If a patient suffered from a more severe type of comorbidity, the less severe CV was set to 0; i.e. patients with a DBC (Diabetes, complicated) CV will never have a DBU (Diabetes, uncomplicated) CV. This screening was performed to avoid collinearity of variables.

-   In other cases, if any ICD10 code which defined a particular CV occurred in secondary diagnoses during the index hospitalisation or any diagnosis up to one year before hospitalisation, then the respective CV was set to 1.

Other input variables in the models were demographic: patient's age (continuous variable), sex (male/female), and place of residence (town/village).

The outcome variable in our models was the occurrence of a patient's death during hospitalisation or up to 365 days after discharge, from now on referred to as 1-year mortality. It is important to mention that the gathered data contained complete information about deaths in Poland. Consequently, the outcome variables were free from missing values.

Logistic regression {#sec2.4}
-------------------

In our models, we employed logistic regression. The logistic regression model links conditional probability with explaining variables through:
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The β~0~, β~1~, ..., β~p~ coefficients are estimated by the maximum likelihood from the training dataset. Having obtained the above mentioned coefficients, one can estimate the probability of *Y* = 1 using the values of explanatory variables *X* ~1~, ..., *X* ~p~ of a record from another (e.g. testing) dataset. In our models, the sum of coefficients β~0~ + β~1~ *X* ~1~ + \... + β*~p~X~p~* is called the Comorbidity Index, or Comorbidity Score, and it is related to the probability of a patient's death through the mentioned relation. Since all of our models had the same outcome variable, it made sense to compare results of patients coming from different Homogeneous Groups through a single-number scale of the Comorbidity Index. The odds ratio (OR) for some binary variables *X* ~i~ in this model is simply an exponent of its corresponding coefficient β~i~. Confidence intervals (CI) for the OR are obtained by exponentiation of β~i~ CI.

At the beginning of the analysis, correlations between comorbidity variables were studied using Pearson correlation. Bidirectional stepwise selection was performed to determine the optimal set of variables. In this procedure, several models with different sets of variables were computed and one minimizing Bayesian information criterion (BIC) was selected. Due to this method, our models had different numbers of CVs and none of them included all. To compare the performance of our models, we produced area under the curve (AUC) statistics (also called C-statistics) for each model. Each analysis was performed in R \[[@cit0012]\] using the pROC package \[[@cit0013]\] at the adopted significance level 0.05.

Heterogeneous group model {#sec2.5}
-------------------------

In order to validate the importance of comorbid factors in predicting 1-year and in-hospital mortality, we first built a logistic regression model containing only demographic variables: patient's age, sex, and place of residence (baseline model). In the next step, a more complex one, which included Elixhauser's comorbidity variables, was built. In this case, variable selection was employed.

Homogeneous group models {#sec2.6}
------------------------

Subsequently, we wanted to verify the hypothesis that splitting our study population into Homogeneous Groups would allow us to separate the effects of variables for each group of diseases. Sub-models were created separately for each Homogeneous Group. At first, we produced models involving only demographic variables and one of the CVs to obtain unadjusted coefficients. These models served a robustness check for the main model including several comorbidity variables.

Study population {#sec2.7}
----------------

All patients who were registered as hospitalised for any reason in the public health system in 2015 and 2014 were considered in the study. Those data were obtained from the national database of hospitalisations, maintained by the National Health Fund (NFZ). The set included 11 156 668 inpatient stay records from 2015, used as the training population, and 10 888 599 from 2014 used as the testing population. As stated before, in order to determine the values of CVs, 1-year history of treatment prior to each hospitalisation was considered. The history consists both of hospital stays and consultations in outpatient clinics which provided healthcare to the patients. [Table I](#t0001){ref-type="table"} presents the partition of the admissions into Homogeneous Groups ([Appendix A](#app01){ref-type="app"}). The most numerous groups, both in 2014 and 2015, were Injury, poisoning, and certain other consequences of external causes (about 14%) and Diseases of the circulatory system (about 13%). Additionally, the number of admissions of each group was over 24 thousand and as a result, that gave the opportunity to create a separate model based on HG. Thanks to our access to data from a long period, we decided to test and train our models on the basis of all hospitalisations from two separate years, which allowed us to validate the models in a better manner. We trained the model on the dataset from 2015 to have the estimated coefficients based on the most recent data. The absolute and relative numbers of admissions are similar and relatively big in particular groups.

###### 

Characteristics of study population -- homogeneous groups

  Group                                                                                                                Number of admissions in 2015         Number of admissions in 2014                
  -------------------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------ ------------ -------
  Heterogeneous Group                                                                                                  11 156 668                           100                            10 888 599   100
  Chapter I -- Certain infectious and parasitic diseases                                                               245 725                              2.20                           237 989      2.19
  Chapter II -- Neoplasms                                                                                              863 019                              7.74                           843 577      7.75
  Chapter III -- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism   97 452                               0.87                           96 758       0.89
  Chapter IV -- Endocrine, nutritional and metabolic diseases                                                          284 565                              2.55                           275 873      2.53
  Chapter V -- Mental and behavioural disorders                                                                        330 453                              2.96                           328 415      3.02
  Chapter VI -- Diseases of the nervous system                                                                         346 625                              3.11                           335 699      3.08
  Chapter VII -- Diseases of the eye and adnexa                                                                        420 138                              3.77                           392 407      3.60
  Chapter VIII -- Diseases of the ear and mastoid process                                                              95 965                               0.86                           94 285       0.87
  Chapter IX -- Diseases of the circulatory system                                                                     1 393 634                            12.49                          1 408 417    12.93
  Chapter X -- Diseases of the respiratory system                                                                      704 231                              6.31                           686 955      6.31
  Chapter XI -- Diseases of the digestive system                                                                       764 138                              6.85                           760 803      6.99
  Chapter XII -- Diseases of the skin and subcutaneous tissue                                                          173 361                              1.55                           170 939      1.57
  Chapter XIII -- Diseases of the musculoskeletal system and connective tissue                                         482 299                              4.32                           454 902      4.18
  Chapter XIV - Diseases of the genitourinary system                                                                   778 587                              6.98                           781 699      7.18
  Chapter XV -- Pregnancy, childbirth and the puerperium                                                               666 100                              5.97                           672 395      6.18
  Chapter XVI -- Certain conditions originating in the perinatal period                                                183 421                              1.64                           180 138      1.65
  Chapter XVII -- Congenital malformations, deformations and chromosomal abnormalities                                 78 973                               0.71                           77 219       0.71
  Chapter XVIII -- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified             664 150                              5.95                           628 576      5.77
  Chapter XIX -- Injury, poisoning and certain other consequences of external causes                                   1 608 679                            14.42                          1 521 496    13.97
  Chapter XX -- External causes of morbidity and mortality                                                             24 558                               0.22                           25 544       0.23
  Chapter XXI -- Factors influencing health status and contact with health services                                    950 595                              8.52                           914 513      8.40
  Chapter XXII -- Codes for special purposes                                                                           0[\*](#tf1-1){ref-type="table-fn"}   0                              0            0

No hospitalization qualified under Chapter XXII HG; therefore no model was produced.

General characteristics of the study population are presented in [Table II](#t0002){ref-type="table"} ([Appendix B](#app02){ref-type="app"}). The training and testing sets were similar with respect to presence of considered variables. Mean age was 46.85 in 2015 and 46.56 in 2014. Comorbid variables with the most occurrences were HPT (932 298 cases in 2015 and 890 541 in 2014), CANCER (811 443 in 2015, 777 929 in 2014) and COPD (651 338 in 2015 and 636 396 in 2014). The least present variable was HIV (2 926 cases in 2015 and 2 637 in 2014); it had almost 9 times fewer occurrences than the second the least present variable, BLA (26 098 in 2015 and 27 305 in 2014).

###### 

Characteristics of study population -- comorbidities[\*](#tf2-1){ref-type="table-fn"}

  Variable                    Number of cases in 2015   Number of cases in 2014               
  --------------------------- ------------------------- ------------------------- ----------- --------------
  1-year mortality            1 056 240                 9.47                      1 028 626   9.45
  Age (mean ± SD) \[years\]   --                        46.85 ±25.77              --          46.56 ±25.77
  Sex (male)                  5 124 119                 45.93                     4 975 071   45.69
  Residence (city)            7 625 768                 68.35                     7 399 383   67.96
  HIV                         2 926                     0.03                      2 637       0.02
  ALCO                        165 362                   1.48                      162 080     1.49
  BLA                         26 098                    0.23                      27 305      0.25
  CA                          501 291                   4.49                      464 001     4.26
  CANCER                      811 443                   7.27                      777 929     7.14
  CHF                         387 327                   3.47                      372 750     3.42
  COAG                        102 187                   0.92                      104 045     0.96
  COPD                        651 338                   5.84                      636 396     5.84
  DA                          89 807                    0.80                      91 149      0.84
  DBC                         406 980                   3.65                      396 422     3.64
  DBU                         207 495                   1.86                      196 347     1.80
  DEP                         240 659                   2.16                      232 512     2.14
  DRUG                        34 662                    0.31                      29 232      0.27
  FED                         149 744                   1.34                      144 892     1.33
  HTC                         368 633                   3.30                      343 630     3.16
  HTU                         391 521                   3.51                      385 301     3.54
  HPT                         932 298                   8.36                      890 541     8.18
  LD                          149 035                   1.34                      142 924     1.31
  LYMP                        70 866                    0.64                      65 980      0.61
  META                        148 243                   1.33                      145 971     1.34
  NEU                         258 500                   2.32                      258 425     2.37
  OBES                        117 913                   1.06                      111 392     1.02
  PARA                        32 194                    0.29                      32 235      0.30
  PCD                         33 821                    0.30                      33 337      0.31
  PSYCH                       54 775                    0.49                      54 399      0.50
  PUD                         26 452                    0.24                      28 239      0.26
  PVD                         261 519                   2.34                      250 902     2.30
  RF                          236 106                   2.12                      223 595     2.05
  RHEU                        133 770                   1.20                      128 371     1.18
  VD                          125 268                   1.12                      116 469     1.07
  WL                          38 395                    0.34                      38 437      0.35

All abbreviations and definitions of variables used in Table I are given in [Appendix B](#app02){ref-type="app"}.

It is important to understand what is considered to be a record. A single record in this study is a hospitalisation, so each patient can have more than one. Furthermore, we analysed a 1-year post-hospitalisation mortality, so one patient can have several records prior to death. Out of 6 924 639 patients served in 2015, 399 946 died in hospital or up to 1 year after the last hospitalisation, but due to the aforementioned methodology, we considered 11 156 668 records with 1 056 240 cases of 1-year mortality. This approach implies that our models could be applied to assess the patient's probability of death upon admission for hospitalisation.

Results {#sec3}
=======

The data sets were characterized by a low correlation coefficient -- the highest Pearson correlation value was 0.25. Therefore, the considered variables were at low risk of multicollinearity.

Heterogeneous group model {#sec3.1}
-------------------------

Comparing the baseline model to the one with CVs, the hypothesis that inserting comorbidities improved the performance of the baseline model was confirmed by the ANOVA likelihood-ratio test (*p* \< 0.01). The model with CVs yielded adjusted coefficients presented in [Table III](#t0003){ref-type="table"}. One more time, the ANOVA likelihood-ratio test was applied as well. The presented results showed that all CVs and demographic variables were found significant (*p* \< 0.05). We also found that META (2.52, *p* \< 0.01) and WL (1.89, *p* \< 0.01) were associated the most with the analysed outcome (excluding intercept). Moreover, there were 9 variables which reduce the probability of death: Residence (--0.064, *p* \< 0.01), CA (--0.13, *p* \< 0.01), DEP (--0.24, *p* \< 0.01), HPT (--0.45, *p* \< 0.01), HTC (--0.42, *p* \< 0.01), HTU (--0.17, *p* \< 0.01), OBES (--0.39, *p* \< 0.01), RHEU (--0.13, *p* \< 0.01), VD (--0.08, *p* \< 0.01). The AUC for the heterogeneous group model was 0.81.

Homogeneous group models {#sec3.2}
------------------------

Sub-models were created separately for each Homogeneous Group. According to [Table IV](#t0005){ref-type="table"}, which presents the number of included CVs in the models, the model built on the Chapter XIX data (Injury, poisoning and certain other consequences of external causes) excluded only two variables -- CA and FD. Twenty-eight variables were included in the models based on data: Chapter II (Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism), Chapter XIV (Diseases of the genitourinary system), Chapter XVIII (Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified). The fewest number of predictors, only 4, were given to the model in the case of Chapter XVI (Certain conditions originating in the perinatal period). As per [Table III](#t0003){ref-type="table"}, predictors which are associated with the explanatory variably are most META -- coefficients were in range of 2.5--3.8 (*p* \< 0.01), except in the models based on Chapter II, Chapter XV, Chapter XVI, where this variable appeared to be insignificant or dropped during stepwise selection; CANCER (0.56--2.8) (*p* \< 0.01), except in Chapter II, Chapter XVI; WL (0.59, 2.4), excluding Chapter IV, Chapter XV, Chapter XVI, Chapter XX. Variable VD was used in the case of 4 models; in other performances, VD resulted in being dropped during selection or insignificant (*p* \> 0.05). Variables DEP, HPT, HTC, HTU, and OBES were found to reduce the probability of a patient's death in every group in which they were significant. There also appeared a few comorbidities which increase death probability in some groups and reduce it in others. These variables are BLA, CA, COPD, DBU, PSYCH, PUD, RHEU, and VD.

###### 

Effects of comorbidities on 1-year mortality of patients in the heterogeneous group and homogeneous groups -- part 1[^1^](#tf3-1){ref-type="table-fn"}

  Parameter             Heterogeneous Group   Chapter I                                    Chapter II                                   Chapter III                                  Chapter IV                                  Chapter V                                    Chapter VI                                  Chapter VII                                 Chapter VIII                                 Chapter IX                                  Chapter X                                    
  --------------------- --------------------- -------------------------------------------- -------------------------------------------- -------------------------------------------- ------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------- ------------------------------------------- -------------------------------------------- -------------------------------------------
  (Intercept)           Coefficient           --6.4[\*\*](#tf3-1){ref-type="table-fn"}     --6.9[\*\*](#tf3-1){ref-type="table-fn"}     --4.0[\*\*](#tf3-1){ref-type="table-fn"}     --5.3[\*\*](#tf3-1){ref-type="table-fn"}    --7.0[\*\*](#tf3-1){ref-type="table-fn"}     --7.2[\*\*](#tf3-1){ref-type="table-fn"}    --7.0[\*\*](#tf3-1){ref-type="table-fn"}    --8.6[\*\*](#tf3-1){ref-type="table-fn"}     --9.1[\*\*](#tf3-1){ref-type="table-fn"}    --7.1[\*\*](#tf3-1){ref-type="table-fn"}     --6.2[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (--6.4; --6.4)        (--7.0; --6.8)                               (--4.0; --3.9)                               (--5.4; --5.2)                               (--7.1; --6.9)                              (--7.2; --7.1)                               (--7.1; --6.9)                              (--8.8; --8.4)                              (--9.5; --8.8)                               (--7.1; --7.0)                              (--6.3; --6.2)                               
  Age                   Coefficient           0.059[\*\*](#tf3-1){ref-type="table-fn"}     0.072[\*\*](#tf3-1){ref-type="table-fn"}     0.039[\*\*](#tf3-1){ref-type="table-fn"}     0.053[\*\*](#tf3-1){ref-type="table-fn"}    0.07[\*\*](#tf3-1){ref-type="table-fn"}      0.069[\*\*](#tf3-1){ref-type="table-fn"}    0.059[\*\*](#tf3-1){ref-type="table-fn"}    0.06[\*\*](#tf3-1){ref-type="table-fn"}      0.066[\*\*](#tf3-1){ref-type="table-fn"}    0.070[\*\*](#tf3-1){ref-type="table-fn"}     0.064[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.059; 0.059)        (0.071; 0.073)                               (0.038; 0.039)                               (0.052; 0.054)                               (0.069; 0.071)                              (0.068; 0.070)                               (0.058; 0.060)                              (0.058; 0.062)                              (0.060; 0.071)                               (0.070; 0.071)                              (0.063; 0.064)                               
  Sex (male)            Coefficient           0.393[\*\*](#tf3-1){ref-type="table-fn"}     0.36[\*\*](#tf3-1){ref-type="table-fn"}      0.45[\*\*](#tf3-1){ref-type="table-fn"}      0.38[\*\*](#tf3-1){ref-type="table-fn"}     0.44[\*\*](#tf3-1){ref-type="table-fn"}      0.58[\*\*](#tf3-1){ref-type="table-fn"}     0.48[\*\*](#tf3-1){ref-type="table-fn"}     0.51[\*\*](#tf3-1){ref-type="table-fn"}      0.65[\*\*](#tf3-1){ref-type="table-fn"}     0.27[\*\*](#tf3-1){ref-type="table-fn"}      0.26[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.389; 0.398)        (0.32; 0.40)                                 (0.44; 0.46)                                 (0.34; 0.42)                                 (0.41; 0.47)                                (0.54; 0.62)                                 (0.45; 0.52)                                (0.46; 0.55)                                (0.47; 0.83)                                 (0.26; 0.28)                                (0.24; 0.27)                                 
  Residence (village)   Coefficient           --0.064[\*\*](#tf3-1){ref-type="table-fn"}   --0.088[\*\*](#tf3-1){ref-type="table-fn"}   --0.044[\*\*](#tf3-1){ref-type="table-fn"}   --0.13[\*\*](#tf3-1){ref-type="table-fn"}   --0.042[\*](#tf4-1){ref-type="table-fn"}     0.045                                       --                                          --0.087[\*\*](#tf3-1){ref-type="table-fn"}   --                                          --0.035[\*\*](#tf3-1){ref-type="table-fn"}   --
  95% CI                (--0.069; --0.059)    (--0.13; --0.049)                            (--0.056; --0.032)                           (--0.17; --0.087)                            (--0.073; --0.01)                           (0.01; 0.08)                                                                             (--0.13; --0.04)                                                                         (--0.046; --0.024)                                                                       
  HIV                   Coefficient           0.8[\*\*](#tf3-1){ref-type="table-fn"}       0.43[\*\*](#tf3-1){ref-type="table-fn"}      0.78[\*\*](#tf3-1){ref-type="table-fn"}      2.9[\*\*](#tf3-1){ref-type="table-fn"}      --                                           --                                          2.2[\*\*](#tf3-1){ref-type="table-fn"}      --                                           --                                          0.82[\*](#tf4-1){ref-type="table-fn"}        1.4[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.67; 0.92)          (0.19; 0.67)                                 (0.40; 1.1)                                  (2.2; 3.7)                                                                                                                            (1.4; 3.0)                                                                                                                           (0.27; 1.3)                                 (0.87; 1.9)                                  
  ALCO                  Coefficient           0.78[\*\*](#tf3-1){ref-type="table-fn"}      0.91[\*\*](#tf3-1){ref-type="table-fn"}      0.44[\*\*](#tf3-1){ref-type="table-fn"}      0.8[\*\*](#tf3-1){ref-type="table-fn"}      1.3[\*\*](#tf3-1){ref-type="table-fn"}       --                                          1.2[\*\*](#tf3-1){ref-type="table-fn"}      1.1[\*\*](#tf3-1){ref-type="table-fn"}       1.2[\*\*](#tf3-1){ref-type="table-fn"}      1.2[\*\*](#tf3-1){ref-type="table-fn"}       0.89[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.76; 0.79)          (0.81; 1.0)                                  (0.39; 0.50)                                 (0.65; 0.94)                                 (1.2; 1.4)                                                                               (1.1; 1.3)                                  (0.89; 1.3)                                 (0.62; 1.8)                                  (1.1; 1.2)                                  (0.83; 0.94)                                 
  BLA                   Coefficient           0.41[\*\*](#tf3-1){ref-type="table-fn"}      0.52[\*\*](#tf3-1){ref-type="table-fn"}      0.37[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.26[\*](#tf4-1){ref-type="table-fn"}        0.75[\*\*](#tf3-1){ref-type="table-fn"}     --                                          0.91[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.51[\*\*](#tf3-1){ref-type="table-fn"}      0.33[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.38; 0.45)          (0.25; 0.78)                                 (0.30; 0.43)                                                                              (0.099; 0.41)                               (0.38; 1.1)                                                                              (0.51; 1.3)                                                                              (0.43; 0.58)                                (0.17; 0.49)                                 
  CA                    Coefficient           --0.13[\*\*](#tf3-1){ref-type="table-fn"}    --                                           --0.14[\*\*](#tf3-1){ref-type="table-fn"}    --0.10[\*\*](#tf3-1){ref-type="table-fn"}   --0.098[\*\*](#tf3-1){ref-type="table-fn"}   0.13[\*\*](#tf3-1){ref-type="table-fn"}     --                                          --                                           --                                          --                                           --0.033
  95% CI                (--0.14; --0.12)                                                   (--0.16; --0.12)                             (--0.16; --0.042)                            (--0.14; --0.055)                           (0.058; 0.2)                                                                                                                                                                                                                  (--0.058; --0.008)                           
  CANCER                Coefficient           1.22[\*\*](#tf3-1){ref-type="table-fn"}      0.96[\*\*](#tf3-1){ref-type="table-fn"}      --                                           1.8[\*\*](#tf3-1){ref-type="table-fn"}      1.5[\*\*](#tf3-1){ref-type="table-fn"}       0.59[\*\*](#tf3-1){ref-type="table-fn"}     1.2[\*\*](#tf3-1){ref-type="table-fn"}      0.77[\*\*](#tf3-1){ref-type="table-fn"}      1.2[\*\*](#tf3-1){ref-type="table-fn"}      0.56[\*\*](#tf3-1){ref-type="table-fn"}      1.0[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (1.21; 1.23)          (0.91; 1.0)                                                                               (1.7; 1.8)                                   (1.5; 1.5)                                  (0.5; 0.68)                                  (1.2; 1.3)                                  (0.71; 0.83)                                (0.91; 1.4)                                  (0.54; 0.58)                                (1.0; 1.1)                                   
  CHF                   Coefficient           0.74[\*\*](#tf3-1){ref-type="table-fn"}      0.85[\*\*](#tf3-1){ref-type="table-fn"}      0.57[\*\*](#tf3-1){ref-type="table-fn"}      0.40[\*\*](#tf3-1){ref-type="table-fn"}     0.71[\*\*](#tf3-1){ref-type="table-fn"}      0.64[\*\*](#tf3-1){ref-type="table-fn"}     0.75[\*\*](#tf3-1){ref-type="table-fn"}     0.84[\*\*](#tf3-1){ref-type="table-fn"}      0.91[\*\*](#tf3-1){ref-type="table-fn"}     --                                           0.69[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.73; 0.75)          (0.79; 0.9)                                  (0.55; 0.59)                                 (0.34; 0.45)                                 (0.67; 0.74)                                (0.57; 0.71)                                 (0.69; 0.81)                                (0.77; 0.9)                                 (0.58; 1.2)                                                                              (0.67; 0.72)                                 
  COAG                  Coefficient           1.15[\*\*](#tf3-1){ref-type="table-fn"}      0.70[\*\*](#tf3-1){ref-type="table-fn"}      0.99[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.64[\*\*](#tf3-1){ref-type="table-fn"}      0.60[\*\*](#tf3-1){ref-type="table-fn"}     0.83[\*\*](#tf3-1){ref-type="table-fn"}     0.81[\*\*](#tf3-1){ref-type="table-fn"}      1.6[\*\*](#tf3-1){ref-type="table-fn"}      0.75[\*\*](#tf3-1){ref-type="table-fn"}      0.86[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (1.13; 1.17)          (0.61; 0.79)                                 (0.96; 1.0)                                                                               (0.51; 0.76)                                (0.43; 0.76)                                 (0.65; 1.0)                                 (0.58; 1.0)                                 (0.91; 2.3)                                  (0.7; 0.8)                                  (0.77; 0.94)                                 
  COPD                  Coefficient           0.16[\*\*](#tf3-1){ref-type="table-fn"}      --                                           0.24[\*\*](#tf3-1){ref-type="table-fn"}      --0.20[\*\*](#tf3-1){ref-type="table-fn"}   --0.15[\*\*](#tf3-1){ref-type="table-fn"}    --                                          --0.074                                     0.27[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.15[\*\*](#tf3-1){ref-type="table-fn"}      --
  95% CI                (0.15; 0.17)                                                       (0.23; 0.26)                                 (--0.27; --0.14)                             (--0.21; --0.10)                                                                         (--0.14; --0.01)                            (0.20; 0.33)                                                                             (0.13; 0.16)                                                                             
  DA                    Coefficient           0.47[\*\*](#tf3-1){ref-type="table-fn"}      0.61[\*\*](#tf3-1){ref-type="table-fn"}      0.32[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.28[\*\*](#tf3-1){ref-type="table-fn"}      0.5[\*\*](#tf3-1){ref-type="table-fn"}      0.57[\*\*](#tf3-1){ref-type="table-fn"}     --                                           --                                          0.51[\*\*](#tf3-1){ref-type="table-fn"}      0.44[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.45; 0.49)          (0.49; 0.73)                                 (0.28; 0.36)                                                                              (0.19; 0.36)                                (0.36; 0.64)                                 (0.39; 0.75)                                                                                                                         (0.46; 0.55)                                (0.36; 0.51)                                 
  DBC                   Coefficient           0.28[\*\*](#tf3-1){ref-type="table-fn"}      0.39[\*\*](#tf3-1){ref-type="table-fn"}      0.29[\*\*](#tf3-1){ref-type="table-fn"}      0.24[\*\*](#tf3-1){ref-type="table-fn"}     --                                           0.4[\*\*](#tf3-1){ref-type="table-fn"}      0.36[\*\*](#tf3-1){ref-type="table-fn"}     0.51[\*\*](#tf3-1){ref-type="table-fn"}      0.75[\*\*](#tf3-1){ref-type="table-fn"}     0.25[\*\*](#tf3-1){ref-type="table-fn"}      0.24[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.27; 0.29)          (0.33; 0.45)                                 (0.26; 0.31)                                 (0.17; 0.31)                                                                             (0.32; 0.48)                                 (0.29; 0.43)                                (0.45; 0.57)                                (0.39; 1.1)                                  (0.23; 0.26)                                (0.21; 0.27)                                 
  DBU                   Coefficient           0.22[\*\*](#tf3-1){ref-type="table-fn"}      --                                           0.25[\*\*](#tf3-1){ref-type="table-fn"}      0.13[\*](#tf3-1){ref-type="table-fn"}       --                                           0.14[\*](#tf3-1){ref-type="table-fn"}       0.24[\*\*](#tf3-1){ref-type="table-fn"}     0.27[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.045[\*\*](#tf3-1){ref-type="table-fn"}     0.087[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.21; 0.23)                                                       (0.22; 0.28)                                 (0.042; 0.23)                                                                            (0.038; 0.25)                                (0.14; 0.33)                                (0.14; 0.39)                                                                             (0.022; 0.068)                              (0.042; 0.13)                                
  DEP                   Coefficient           --0.24[\*\*](#tf3-1){ref-type="table-fn"}    --0.36[\*\*](#tf3-1){ref-type="table-fn"}    --0.098[\*\*](#tf3-1){ref-type="table-fn"}   --0.15                                      --0.24[\*\*](#tf3-1){ref-type="table-fn"}    --                                          --0.26[\*\*](#tf3-1){ref-type="table-fn"}   --                                           --                                          --0.43[\*\*](#tf3-1){ref-type="table-fn"}    --0.20[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (--0.26; --0.22)      (--0.49; --0.23)                             (--0.13; --0.063)                            (--0.28; --0.016)                            (--0.34; --0.14)                                                                         (--0.37; --0.16)                                                                                                                     (--0.47; --0.38)                            (--0.26; --0.14)                             
  DRUG                  Coefficient           0.11[\*\*](#tf3-1){ref-type="table-fn"}      --                                           0.16                                         --                                          --                                           --                                          --                                          --                                           --                                          0.17[\*](#tf3-1){ref-type="table-fn"}        0.23[\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.062; 0.151)                                                     (0.023; 0.29)                                                                                                                                                                                                                                                                                                           (0.058; 0.29)                               (0.072; 0.39)                                
  FED                   Coefficient           0.89[\*\*](#tf3-1){ref-type="table-fn"}      0.50[\*\*](#tf3-1){ref-type="table-fn"}      1.2[\*\*](#tf3-1){ref-type="table-fn"}       0.59[\*\*](#tf3-1){ref-type="table-fn"}     --                                           0.45[\*\*](#tf3-1){ref-type="table-fn"}     1.0[\*\*](#tf3-1){ref-type="table-fn"}      0.58[\*\*](#tf3-1){ref-type="table-fn"}      1.1[\*\*](#tf3-1){ref-type="table-fn"}      0.78[\*\*](#tf3-1){ref-type="table-fn"}      0.80[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.88; 0.91)          (0.43; 0.58)                                 (1.1; 1.2)                                   (0.49; 0.70)                                                                             (0.36; 0.54)                                 (0.90; 1.1)                                 (0.39; 0.77)                                (0.44; 1.7)                                  (0.75; 0.81)                                (0.75; 0.85)                                 
  HPT                   Coefficient           --0.45[\*\*](#tf3-1){ref-type="table-fn"}    --0.54[\*\*](#tf3-1){ref-type="table-fn"}    --0.42[\*\*](#tf3-1){ref-type="table-fn"}    --0.18[\*\*](#tf3-1){ref-type="table-fn"}   --                                           --0.38[\*\*](#tf3-1){ref-type="table-fn"}   --0.49[\*\*](#tf3-1){ref-type="table-fn"}   --0.49[\*\*](#tf3-1){ref-type="table-fn"}    --0.53                                      --0.62[\*\*](#tf3-1){ref-type="table-fn"}    --0.51[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (--0.46; --0.43)      (--0.65; --0.44)                             (--0.45; --0.39)                             (--0.27; --0.091)                                                                        (--0.50; --0.27)                             (--0.59; --0.39)                            (--0.6; --0.37)                             (--1.0; --0.089)                             (--0.65; --0.59)                            (--0.56; --0.46)                             
  HTC                   Coefficient           --0.42[\*\*](#tf3-1){ref-type="table-fn"}    --0.53[\*\*](#tf3-1){ref-type="table-fn"}    --0.21[\*\*](#tf3-1){ref-type="table-fn"}    --0.3[\*\*](#tf3-1){ref-type="table-fn"}    --0.69[\*\*](#tf3-1){ref-type="table-fn"}    --0.41[\*\*](#tf3-1){ref-type="table-fn"}   --0.5[\*\*](#tf3-1){ref-type="table-fn"}    --0.29[\*\*](#tf3-1){ref-type="table-fn"}    --0.98[\*\*](#tf3-1){ref-type="table-fn"}   --                                           --0.66[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (--0.43; --0.41)      (--0.60; --0.47)                             (--0.23; --0.18)                             (--0.37; --0.23)                             (--0.74; --0.64)                            (--0.49; --0.32)                             (--0.57; --0.43)                            (--0.37; --0.21)                            (--1.5; --0.55)                                                                          (--0.69; --0.63)                             
  HTU                   Coefficient           --0.17[\*\*](#tf3-1){ref-type="table-fn"}    --0.44[\*\*](#tf3-1){ref-type="table-fn"}    --0.026[\*\*](#tf3-1){ref-type="table-fn"}   --0.21[\*\*](#tf3-1){ref-type="table-fn"}   --0.54[\*\*](#tf3-1){ref-type="table-fn"}    --0.12[\*\*](#tf3-1){ref-type="table-fn"}   --0.24[\*\*](#tf3-1){ref-type="table-fn"}   --0.18[\*\*](#tf3-1){ref-type="table-fn"}    --0.25                                      --                                           --0.40[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (--0.18; --0.16)      (--0.49; --0.4)                              (--0.04; --0.011)                            (--0.26; --0.16)                             (--0.57; --0.5)                             (--0.17; --0.076)                            (--0.28; --0.19)                            (--0.24; --0.12)                            (--0.49; --0.011)                                                                        (--0.42; --0.38)                             
  LD                    Coefficient           0.48[\*\*](#tf3-1){ref-type="table-fn"}      0.66[\*\*](#tf3-1){ref-type="table-fn"}      0.30[\*\*](#tf3-1){ref-type="table-fn"}      0.22[\*\*](#tf3-1){ref-type="table-fn"}     0.12[\*](#tf3-1){ref-type="table-fn"}        0.53[\*\*](#tf3-1){ref-type="table-fn"}     0.44[\*\*](#tf3-1){ref-type="table-fn"}     0.27[\*](#tf3-1){ref-type="table-fn"}        0.65                                        0.44[\*\*](#tf3-1){ref-type="table-fn"}      0.45[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.46; 0.49)          (0.56; 0.75)                                 (0.27; 0.34)                                 (0.13; 0.32)                                 (0.04; 0.20)                                (0.46; 0.59)                                 (0.33; 0.56)                                (0.093; 0.45)                               (0.062; 1.2)                                 (0.41; 0.48)                                (0.38; 0.51)                                 
  LYMP                  Coefficient           0.55[\*\*](#tf3-1){ref-type="table-fn"}      1.1[\*\*](#tf3-1){ref-type="table-fn"}       --                                           1.1[\*\*](#tf3-1){ref-type="table-fn"}      1.2[\*\*](#tf3-1){ref-type="table-fn"}       0.93[\*\*](#tf3-1){ref-type="table-fn"}     1.2[\*\*](#tf3-1){ref-type="table-fn"}      1.3[\*\*](#tf3-1){ref-type="table-fn"}       1.1                                         0.96[\*\*](#tf3-1){ref-type="table-fn"}      1.1[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.53; 0.57)          (1.0; 1.3)                                                                                (1.0; 1.2)                                   (1.0; 1.3)                                  (0.58; 1.3)                                  (1.0; 1.5)                                  (1.1; 1.4)                                  (0.12; 1.9)                                  (0.90; 1.0)                                 (1.0; 1.2)                                   
  META                  Coefficient           2.52[\*\*](#tf3-1){ref-type="table-fn"}      2.9[\*\*](#tf3-1){ref-type="table-fn"}       --                                           3.0[\*\*](#tf3-1){ref-type="table-fn"}      3.8[\*\*](#tf3-1){ref-type="table-fn"}       2.6[\*\*](#tf3-1){ref-type="table-fn"}      3.7[\*\*](#tf3-1){ref-type="table-fn"}      2.6[\*\*](#tf3-1){ref-type="table-fn"}       2.7[\*\*](#tf3-1){ref-type="table-fn"}      2.8[\*\*](#tf3-1){ref-type="table-fn"}       2.9[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (2.51; 2.53)          (2.7; 3.1)                                                                                (2.9; 3.1)                                   (3.7; 3.9)                                  (2.3; 3)                                     (3.5; 3.8)                                  (2.4; 2.8)                                  (1.9; 3.4)                                   (2.7; 2.9)                                  (2.8; 2.9)                                   
  NEU                   Coefficient           0.52[\*\*](#tf3-1){ref-type="table-fn"}      0.79[\*\*](#tf3-1){ref-type="table-fn"}      0.44[\*\*](#tf3-1){ref-type="table-fn"}      0.27[\*\*](#tf3-1){ref-type="table-fn"}     0.70[\*\*](#tf3-1){ref-type="table-fn"}      0.54[\*\*](#tf3-1){ref-type="table-fn"}     --                                          0.41[\*\*](#tf3-1){ref-type="table-fn"}      1.0[\*\*](#tf3-1){ref-type="table-fn"}      0.52[\*\*](#tf3-1){ref-type="table-fn"}      0.98[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.5099; 0.5342)      (0.71; 0.87)                                 (0.4; 0.47)                                  (0.16; 0.38)                                 (0.63; 0.77)                                (0.49; 0.59)                                                                             (0.29; 0.53)                                (0.6; 1.4)                                   (0.49; 0.54)                                (0.94; 1.0)                                  
  OBES                  Coefficient           --0.39[\*\*](#tf3-1){ref-type="table-fn"}    --0.34[\*\*](#tf3-1){ref-type="table-fn"}    --0.41[\*\*](#tf3-1){ref-type="table-fn"}    --0.27[\*](#tf3-1){ref-type="table-fn"}     --                                           --0.36[\*](#tf3-1){ref-type="table-fn"}     --0.55[\*\*](#tf3-1){ref-type="table-fn"}   --0.62[\*\*](#tf3-1){ref-type="table-fn"}    --                                          --0.45[\*\*](#tf3-1){ref-type="table-fn"}    --0.19[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (--0.41; --0.36)      (--0.52; --0.17)                             (--0.46; --0.35)                             (--0.46; --0.089)                                                                        (--0.58; --0.15)                             (--0.73; --0.38)                            (--0.91; --0.35)                                                                         (--0.49; --0.41)                            (--0.27; --0.12)                             
  PARA                  Coefficient           0.84[\*\*](#tf3-1){ref-type="table-fn"}      0.94[\*\*](#tf3-1){ref-type="table-fn"}      1.1[\*\*](#tf3-1){ref-type="table-fn"}       --                                          0.54[\*\*](#tf3-1){ref-type="table-fn"}      0.37[\*](#tf3-1){ref-type="table-fn"}       --                                          0.79[\*\*](#tf3-1){ref-type="table-fn"}      1.4[\*](#tf3-1){ref-type="table-fn"}        0.72[\*\*](#tf3-1){ref-type="table-fn"}      1.2[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.81; 0.87)          (0.74; 1.1)                                  (1; 1.2)                                                                                  (0.37; 0.72)                                (0.12; 0.6)                                                                              (0.44; 1.1)                                 (0.36; 2.3)                                  (0.66; 0.77)                                (1.1; 1.3)                                   
  PCD                   Coefficient           0.82[\*\*](#tf3-1){ref-type="table-fn"}      0.92[\*\*](#tf3-1){ref-type="table-fn"}      0.76[\*\*](#tf3-1){ref-type="table-fn"}      0.26[\*](#tf3-1){ref-type="table-fn"}       0.50[\*\*](#tf3-1){ref-type="table-fn"}      0.72[\*\*](#tf3-1){ref-type="table-fn"}     0.68[\*\*](#tf3-1){ref-type="table-fn"}     0.44[\*\*](#tf3-1){ref-type="table-fn"}      1.9[\*\*](#tf3-1){ref-type="table-fn"}      --                                           0.75[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.79; 0.84)          (0.75; 1.1)                                  (0.71; 0.82)                                 (0.063; 0.46)                                (0.33; 0.67)                                (0.49; 0.94)                                 (0.47; 0.89)                                (0.17; 0.7)                                 (1.0; 2.6)                                                                               (0.69; 0.8)                                  
  PSYCH                 Coefficient           0.42[\*\*](#tf3-1){ref-type="table-fn"}      0.79[\*\*](#tf3-1){ref-type="table-fn"}      0.37[\*\*](#tf3-1){ref-type="table-fn"}      0.44[\*\*](#tf3-1){ref-type="table-fn"}     0.45[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.81[\*\*](#tf3-1){ref-type="table-fn"}     0.52[\*\*](#tf3-1){ref-type="table-fn"}      --                                          0.75[\*\*](#tf3-1){ref-type="table-fn"}      0.73[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.39; 0.44)          (0.63; 0.95)                                 (0.3; 0.44)                                  (0.23; 0.65)                                 (0.31; 0.58)                                                                             (0.65; 0.96)                                (0.22; 0.8)                                                                              (0.69; 0.81)                                (0.65; 0.81)                                 
  PUD                   Coefficient           0.26[\*\*](#tf3-1){ref-type="table-fn"}      --                                           0.4[\*\*](#tf3-1){ref-type="table-fn"}       --                                          --                                           --                                          --                                          --0.77[\*](#tf3-1){ref-type="table-fn"}      --                                          --                                           --
  95% CI                (0.23; 0.29)                                                       (0.34; 0.47)                                                                                                                                                                                                                   (--1.4; --0.25)                                                                                                                                                                   
  PVD                   Coefficient           0.31[\*\*](#tf3-1){ref-type="table-fn"}      0.47[\*\*](#tf3-1){ref-type="table-fn"}      0.20[\*\*](#tf3-1){ref-type="table-fn"}      0.18[\*\*](#tf3-1){ref-type="table-fn"}     0.39[\*\*](#tf3-1){ref-type="table-fn"}      0.41[\*\*](#tf3-1){ref-type="table-fn"}     0.31[\*\*](#tf3-1){ref-type="table-fn"}     0.35[\*\*](#tf3-1){ref-type="table-fn"}      --                                          --                                           0.36[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.30; 0.32)          (0.41; 0.53)                                 (0.18; 0.22)                                 (0.12; 0.25)                                 (0.35; 0.43)                                (0.33; 0.49)                                 (0.24; 0.37)                                (0.28; 0.43)                                                                                                                         (0.33; 0.38)                                 
  RF                    Coefficient           0.57[\*\*](#tf3-1){ref-type="table-fn"}      0.66[\*\*](#tf3-1){ref-type="table-fn"}      0.28[\*\*](#tf3-1){ref-type="table-fn"}      0.4[\*\*](#tf3-1){ref-type="table-fn"}      0.48[\*\*](#tf3-1){ref-type="table-fn"}      0.43[\*\*](#tf3-1){ref-type="table-fn"}     0.44[\*\*](#tf3-1){ref-type="table-fn"}     0.68[\*\*](#tf3-1){ref-type="table-fn"}      0.66[\*](#tf3-1){ref-type="table-fn"}       0.64[\*\*](#tf3-1){ref-type="table-fn"}      0.55[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (0.56; 0.58)          (0.6; 0.72)                                  (0.26; 0.31)                                 (0.33; 0.46)                                 (0.43; 0.52)                                (0.30; 0.55)                                 (0.35; 0.54)                                (0.59; 0.76)                                (0.23; 1.1)                                  (0.62; 0.66)                                (0.51; 0.58)                                 
  RHEU                  Coefficient           --0.13[\*\*](#tf3-1){ref-type="table-fn"}    0.19[\*\*](#tf3-1){ref-type="table-fn"}      --0.21[\*\*](#tf3-1){ref-type="table-fn"}    --0.36[\*\*](#tf3-1){ref-type="table-fn"}   --0.19[\*](#tf3-1){ref-type="table-fn"}      --0.60[\*\*](#tf3-1){ref-type="table-fn"}   --                                          0.22[\*](#tf3-1){ref-type="table-fn"}        --                                          --0.074[\*\*](#tf3-1){ref-type="table-fn"}   --
  95% CI                (--0.15; --0.11)      (0.083; 0.30)                                (--0.26; --0.17)                             (--0.48; --0.24)                             (--0.31; --0.072)                           (--0.86; --0.35)                                                                         (0.083; 0.35)                                                                            (--0.11; --0.035)                                                                        
  VD                    Coefficient           --0.08[\*\*](#tf3-1){ref-type="table-fn"}    --                                           --0.15[\*\*](#tf3-1){ref-type="table-fn"}    --                                          --                                           0.15                                        --                                          --                                           --                                          --                                           --
  95% CI                (--0.09; --0.06)                                                   (--0.18; --0.11)                                                                                                                      (0.016; 0.28)                                                                                                                                                                                                                                                              
  WL                    Coefficient           1.89[\*\*](#tf3-1){ref-type="table-fn"}      1.7[\*\*](#tf3-1){ref-type="table-fn"}       2[\*\*](#tf3-1){ref-type="table-fn"}         1.1[\*\*](#tf3-1){ref-type="table-fn"}      --                                           1.2[\*\*](#tf3-1){ref-type="table-fn"}      1.9[\*\*](#tf3-1){ref-type="table-fn"}      0.59                                         1.8                                         1.8[\*\*](#tf3-1){ref-type="table-fn"}       1.7[\*\*](#tf3-1){ref-type="table-fn"}
  95% CI                (1.857; 1.905)        (1.6; 1.9)                                   (1.9; 2)                                     (0.98; 1.3)                                                                              (0.98; 1.3)                                  (1.7; 2.1)                                  (0.089; 1.0)                                (0.14; 2.9)                                  (1.7; 1.8)                                  (1.7; 1.8)                                   

The mark "--" in the table denotes variables that were dropped either during stepwise selection or due to their statistical insignificance (p \> 5%). One asterisk (\*) next to a coefficient denotes a p \< 1%, two asterisks (\*\*) denote a p \< 0.1%.

###### 

Effects of comorbidities on 1-year mortality of patients in the Heterogeneous Group and Homogeneous Groups -- part 2[^1^](#tf4-1){ref-type="table-fn"}

  Parameter             Chapter XI           Chapter XII                                  Chapter XIII                                Chapter XIV                                 Chapter XV                                   Chapter XVI                                 Chapter XVII                               Chapter XVIII                               Chapter XIX                                 Chapter XX                                  Chapter XXI                                
  --------------------- -------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------ ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------ --------------------------------------------
  (Intercept)           Coefficient          --6.3[\*\*](#tf4-1){ref-type="table-fn"}     --8.0[\*\*](#tf4-1){ref-type="table-fn"}    --9.1[\*\*](#tf4-1){ref-type="table-fn"}    --8.7[\*\*](#tf4-1){ref-type="table-fn"}     --11.0[\*\*](#tf4-1){ref-type="table-fn"}   --8.3[\*\*](#tf4-1){ref-type="table-fn"}   --5.4[\*\*](#tf4-1){ref-type="table-fn"}    --6.8[\*\*](#tf4-1){ref-type="table-fn"}    --8.8[\*\*](#tf4-1){ref-type="table-fn"}    --7.9[\*\*](#tf4-1){ref-type="table-fn"}   --4.8[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--6.4; --6.3)       (--8.1; --7.8)                               (--9.2; --9)                                (--8.8; --8.7)                              (--12.0; --9.9)                              (--8.6; --8.0)                              (--5.5; --5.2)                             (--6.8; --6.7)                              (--8.9; --8.8)                              (--8.4; --7.5)                              (--4.8; --4.8)                             
  Age                   Coefficient          0.056[\*\*](#tf4-1){ref-type="table-fn"}     0.078[\*\*](#tf4-1){ref-type="table-fn"}    0.073[\*\*](#tf4-1){ref-type="table-fn"}    0.085[\*\*](#tf4-1){ref-type="table-fn"}     0.072[\*\*](#tf4-1){ref-type="table-fn"}    0.1[\*\*](#tf4-1){ref-type="table-fn"}     0.029[\*\*](#tf4-1){ref-type="table-fn"}    0.065[\*\*](#tf4-1){ref-type="table-fn"}    0.084[\*\*](#tf4-1){ref-type="table-fn"}    0.064[\*\*](#tf4-1){ref-type="table-fn"}   0.032[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.056; 0.057)       (0.076; 0.080)                               (0.071; 0.075)                              (0.084; 0.086)                              (0.047; 0.097)                               (0.085; 0.12)                               (0.026; 0.032)                             (0.060; 0.061)                              (0.084; 0.085)                              (0.059; 0.070)                              (0.032; 0.033)                             
  Sex (male)            Coefficient          0.24[\*\*](#tf4-1){ref-type="table-fn"}      0.14[\*\*](#tf4-1){ref-type="table-fn"}     0.49[\*\*](#tf4-1){ref-type="table-fn"}     0.26[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         0.21[\*](#tf4-1){ref-type="table-fn"}       0.36[\*\*](#tf4-1){ref-type="table-fn"}     0.53[\*\*](#tf4-1){ref-type="table-fn"}     0.70[\*\*](#tf4-1){ref-type="table-fn"}    0.43[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.22; 0.26)         (0.096; 0.19)                                (0.45; 0.54)                                (0.24; 0.28)                                                                                                                         (0.082; 0.34)                              (0.34; 0.38)                                (0.51; 0.55)                                (0.51; 0.90)                                (0.42; 0.44)                               
  Residence (village)   Coefficient          --0.076[\*\*](#tf4-1){ref-type="table-fn"}   --0.071[\*](#tf4-1){ref-type="table-fn"}    --                                          --0.023                                      --                                          --                                         --0.31[\*\*](#tf4-1){ref-type="table-fn"}   --0.12[\*\*](#tf4-1){ref-type="table-fn"}   --0.08[\*\*](#tf4-1){ref-type="table-fn"}   --                                         --0.033[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--0.095; --0.056)   (--0.12; --0.022)                                                                        (--0.046; --0.001)                                                                                                                   (--0.48; --0.15)                           (--0.14; --0.098)                           (--0.1; --0.058)                                                                        (--0.045; --0.021)                         
  HIV                   Coefficient          1.1[\*](#tf4-1){ref-type="table-fn"}         1.3                                         2.0[\*](#tf4-1){ref-type="table-fn"}        2.1[\*\*](#tf4-1){ref-type="table-fn"}       --                                          --                                         --                                          1.6[\*\*](#tf4-1){ref-type="table-fn"}      0.74[\*](#tf4-1){ref-type="table-fn"}       --                                         --
  95% CI                (0.38; 1.7)          (0.018; 2.3)                                 (0.18; 3.3)                                 (1.1; 2.9)                                                                                                                                                                      (1.0; 2.0)                                  (0.19; 1.2)                                                                                                                        
  ALCO                  Coefficient          1.3[\*\*](#tf4-1){ref-type="table-fn"}       1.2[\*\*](#tf4-1){ref-type="table-fn"}      0.86[\*\*](#tf4-1){ref-type="table-fn"}     1.4[\*\*](#tf4-1){ref-type="table-fn"}       2.2[\*\*](#tf4-1){ref-type="table-fn"}      --                                         --                                          0.79[\*\*](#tf4-1){ref-type="table-fn"}     1.3[\*\*](#tf4-1){ref-type="table-fn"}      1.2[\*\*](#tf4-1){ref-type="table-fn"}     0.36[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (1.3; 1.3)           (1.0; 1.3)                                   (0.68; 1.0)                                 (1.3; 1.5)                                  (1.2; 2.9)                                                                                                                          (0.72; 0.85)                                (1.2; 1.3)                                  (0.98; 1.5)                                 (0.30; 0.42)                               
  BLA                   Coefficient          0.32[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                          1.0[\*\*](#tf4-1){ref-type="table-fn"}       --                                          --                                         --                                          --                                          --0.39[\*](#tf4-1){ref-type="table-fn"}     --                                         --0.15[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.22; 0.41)                                                                                                  (0.88; 1.1)                                                                                                                                                                                                                 (--0.64; --0.15)                                                                        (--0.22; --0.074)                          
  CA                    Coefficient          --0.15[\*\*](#tf4-1){ref-type="table-fn"}    --                                          0.13[\*\*](#tf4-1){ref-type="table-fn"}     --                                           1.0[\*](#tf4-1){ref-type="table-fn"}        --                                         --                                          --0.24[\*\*](#tf4-1){ref-type="table-fn"}   --                                          --                                         --
  95% CI                (--0.18; --0.12)                                                  (0.058; 0.21)                                                                           (0.18; 1.7)                                                                                                                         (--0.27; --0.20)                                                                                                                                                               
  CANCER                Coefficient          1.1[\*\*](#tf4-1){ref-type="table-fn"}       0.80[\*\*](#tf4-1){ref-type="table-fn"}     0.97[\*\*](#tf4-1){ref-type="table-fn"}     1.1[\*\*](#tf4-1){ref-type="table-fn"}       2.8[\*\*](#tf4-1){ref-type="table-fn"}      --                                         0.83[\*\*](#tf4-1){ref-type="table-fn"}     1.7[\*\*](#tf4-1){ref-type="table-fn"}      0.68[\*\*](#tf4-1){ref-type="table-fn"}     0.87[\*\*](#tf4-1){ref-type="table-fn"}    1.7[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (1.0; 1.1)           (0.72; 0.88)                                 (0.90; 1.0)                                 (1.1; 1.2)                                  (2.0; 3.5)                                                                               (0.52; 1.1)                                (1.7; 1.7)                                  (0.64; 0.72)                                (0.54; 1.2)                                 (1.6; 1.7)                                 
  CHF                   Coefficient          0.95[\*\*](#tf4-1){ref-type="table-fn"}      0.94[\*\*](#tf4-1){ref-type="table-fn"}     0.90[\*\*](#tf4-1){ref-type="table-fn"}     1.0[\*\*](#tf4-1){ref-type="table-fn"}       --                                          3.0[\*\*](#tf4-1){ref-type="table-fn"}     1.8[\*\*](#tf4-1){ref-type="table-fn"}      0.83[\*\*](#tf4-1){ref-type="table-fn"}     0.86[\*\*](#tf4-1){ref-type="table-fn"}     0.72[\*\*](#tf4-1){ref-type="table-fn"}    0.29[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.93; 0.98)         (0.88; 1.0)                                  (0.83; 0.98)                                (1.0; 1.1)                                                                               (2.1; 3.7)                                  (1.6; 1.9)                                 (0.80; 0.87)                                (0.82; 0.9)                                 (0.37; 1.1)                                 (0.26; 0.32)                               
  COAG                  Coefficient          1.6[\*\*](#tf4-1){ref-type="table-fn"}       0.97[\*\*](#tf4-1){ref-type="table-fn"}     0.79[\*\*](#tf4-1){ref-type="table-fn"}     1.1[\*\*](#tf4-1){ref-type="table-fn"}       --                                          --                                         0.99[\*\*](#tf4-1){ref-type="table-fn"}     0.95[\*\*](#tf4-1){ref-type="table-fn"}     0.98[\*\*](#tf4-1){ref-type="table-fn"}     --                                         0.69[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (1.6; 1.6)           (0.77; 1.2)                                  (0.59; 0.99)                                (0.98; 1.2)                                                                                                                          (0.56; 1.4)                                (0.86; 1.0)                                 (0.87; 1.1)                                                                             (0.65; 0.72)                               
  COPD                  Coefficient          --0.14[\*\*](#tf4-1){ref-type="table-fn"}    --0.26[\*\*](#tf4-1){ref-type="table-fn"}   0.15[\*\*](#tf4-1){ref-type="table-fn"}     --0.089[\*\*](#tf4-1){ref-type="table-fn"}   --                                          --                                         --                                          --0.05[\*](#tf4-1){ref-type="table-fn"}     --0.18[\*\*](#tf4-1){ref-type="table-fn"}   --                                         0.41[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--0.18; --0.11)     (--0.35; --0.17)                             (0.076; 0.23)                               (--0.13; --0.051)                                                                                                                                                               (--0.086; --0.013)                          (--0.23; --0.14)                                                                        (0.39; 0.43)                               
  DA                    Coefficient          0.24[\*\*](#tf4-1){ref-type="table-fn"}      0.70[\*\*](#tf4-1){ref-type="table-fn"}     0.46[\*\*](#tf4-1){ref-type="table-fn"}     0.70[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         --                                          0.32[\*\*](#tf4-1){ref-type="table-fn"}     0.36[\*\*](#tf4-1){ref-type="table-fn"}     --                                         0.15[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.18; 0.30)         (0.53; 0.87)                                 (0.26; 0.66)                                (0.63; 0.77)                                                                                                                                                                    (0.22; 0.42)                                (0.25; 0.47)                                                                            (0.099; 0.20)                              
  DBC                   Coefficient          0.40[\*\*](#tf4-1){ref-type="table-fn"}      0.48[\*\*](#tf4-1){ref-type="table-fn"}     0.49[\*\*](#tf4-1){ref-type="table-fn"}     0.53[\*\*](#tf4-1){ref-type="table-fn"}      1.9[\*\*](#tf4-1){ref-type="table-fn"}      --                                         0.40                                        0.37[\*\*](#tf4-1){ref-type="table-fn"}     0.40[\*\*](#tf4-1){ref-type="table-fn"}     --                                         0.21[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.37; 0.44)         (0.41; 0.55)                                 (0.40; 0.58)                                (0.50; 0.57)                                (0.87; 2.8)                                                                              (0.011; 0.77)                              (0.33; 0.42)                                (0.34; 0.45)                                                                            (0.18; 0.24)                               
  DBU                   Coefficient          0.22[\*\*](#tf4-1){ref-type="table-fn"}      0.22[\*\*](#tf4-1){ref-type="table-fn"}     0.15                                        0.27[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         --                                          0.29[\*\*](#tf4-1){ref-type="table-fn"}     0.29[\*\*](#tf4-1){ref-type="table-fn"}     --1.2                                      0.16[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.18; 0.27)         (0.095; 0.35)                                (0.012; 0.29)                               (0.21; 0.33)                                                                                                                                                                    (0.23; 0.36)                                (0.22; 0.37)                                (--2.7; --0.23)                             (0.13; 0.19)                               
  DEP                   Coefficient          --0.34[\*\*](#tf4-1){ref-type="table-fn"}    --0.54[\*\*](#tf4-1){ref-type="table-fn"}   --0.34[\*\*](#tf4-1){ref-type="table-fn"}   --0.34[\*\*](#tf4-1){ref-type="table-fn"}    --                                          --                                         --                                          --0.52[\*\*](#tf4-1){ref-type="table-fn"}   --0.28[\*\*](#tf4-1){ref-type="table-fn"}   --                                         --0.055[\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--0.41; --0.28)     (--0.74; --0.35)                             (--0.50; --0.18)                            (--0.42; --0.25)                                                                                                                                                                (--0.60; --0.45)                            (--0.35; --0.20)                                                                        (--0.089; --0.021)                         
  Parameter             Chapter XI           Chapter XII                                  Chapter XIII                                Chapter XIV                                 Chapter XV                                   Chapter XVI                                 Chapter XVII                               Chapter XVIII                               Chapter XIX                                 Chapter XX                                  Chapter XXI                                
  DRUG                  Coefficient          --                                           --                                          0.93[\*\*](#tf4-1){ref-type="table-fn"}     0.31                                         --                                          --                                         --                                          --                                          0.78[\*\*](#tf4-1){ref-type="table-fn"}     0.66                                       0.34[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                                                                                  (0.56; 1.3)                                 (0.069; 0.55)                                                                                                                                                                                                               (0.67; 0.89)                                (0.072; 1.2)                                (0.20; 0.47)                               
  FED                   Coefficient          0.72[\*\*](#tf4-1){ref-type="table-fn"}      1.5[\*\*](#tf4-1){ref-type="table-fn"}      0.79[\*\*](#tf4-1){ref-type="table-fn"}     1.1[\*\*](#tf4-1){ref-type="table-fn"}       --                                          5.4[\*\*](#tf4-1){ref-type="table-fn"}     0.66[\*](#tf4-1){ref-type="table-fn"}       0.67[\*\*](#tf4-1){ref-type="table-fn"}     0.7[\*\*](#tf4-1){ref-type="table-fn"}      --                                         0.71[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.67; 0.77)         (1.4; 1.6)                                   (0.61; 0.96)                                (1.1; 1.1)                                                                               (3.3; 6.8)                                  (0.17; 1.1)                                (0.61; 0.73)                                (0.62; 0.77)                                                                            (0.66; 0.75)                               
  HPT                   Coefficient          --0.56[\*\*](#tf4-1){ref-type="table-fn"}    --0.82[\*\*](#tf4-1){ref-type="table-fn"}   --0.62[\*\*](#tf4-1){ref-type="table-fn"}   --0.57[\*\*](#tf4-1){ref-type="table-fn"}    --                                          --                                         --                                          --0.62[\*\*](#tf4-1){ref-type="table-fn"}   --0.69[\*\*](#tf4-1){ref-type="table-fn"}   --                                         --0.15[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--0.61; --0.50)     (--0.97; --0.67)                             (--0.75; --0.50)                            (--0.63; --0.51)                                                                                                                                                                (--0.69; --0.56)                            (--0.77; --0.61)                                                                        (--0.18; --0.13)                           
  HTC                   Coefficient          --0.67[\*\*](#tf4-1){ref-type="table-fn"}    --0.50[\*\*](#tf4-1){ref-type="table-fn"}   --0.43[\*\*](#tf4-1){ref-type="table-fn"}   --0.17[\*\*](#tf4-1){ref-type="table-fn"}    --                                          --                                         --0.97[\*\*](#tf4-1){ref-type="table-fn"}   --0.61[\*\*](#tf4-1){ref-type="table-fn"}   --0.58[\*\*](#tf4-1){ref-type="table-fn"}   --                                         --0.21[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--0.71; --0.64)     (--0.59; --0.40)                             (--0.53; --0.35)                            (--0.21; --0.14)                                                                                                                     (--1.3; --0.69)                            (--0.65; --0.57)                            (--0.63; --0.53)                                                                        (--0.23; --0.18)                           
  HTU                   Coefficient          --0.39[\*\*](#tf4-1){ref-type="table-fn"}    --0.39[\*\*](#tf4-1){ref-type="table-fn"}   --                                          --0.099[\*\*](#tf4-1){ref-type="table-fn"}   1.3[\*](#tf4-1){ref-type="table-fn"}        --                                         --0.52[\*\*](#tf4-1){ref-type="table-fn"}   --0.3[\*\*](#tf4-1){ref-type="table-fn"}    --0.21[\*\*](#tf4-1){ref-type="table-fn"}   --                                         --0.11[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--0.42; --0.37)     (--0.45; --0.33)                                                                         (--0.13; --0.071)                           (0.39; 2.0)                                                                              (--0.78; --0.28)                           (--0.33; --0.27)                            (--0.25; --0.18)                                                                        (--0.13; --0.097)                          
  LD                    Coefficient          --                                           0.29[\*\*](#tf4-1){ref-type="table-fn"}     0.48[\*\*](#tf4-1){ref-type="table-fn"}     0.77[\*\*](#tf4-1){ref-type="table-fn"}      --                                          3.8[\*\*](#tf4-1){ref-type="table-fn"}     0.57[\*](#tf4-1){ref-type="table-fn"}       0.71[\*\*](#tf4-1){ref-type="table-fn"}     0.64[\*\*](#tf4-1){ref-type="table-fn"}     0.73[\*\*](#tf4-1){ref-type="table-fn"}    0.28[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                                     (0.13; 0.44)                                 (0.33; 0.64)                                (0.70; 0.83)                                                                             (1.5; 5.6)                                  (0.17; 0.94)                               (0.65; 0.77)                                (0.56; 0.71)                                (0.29; 1.1)                                 (0.24; 0.32)                               
  LYMP                  Coefficient          0.82[\*\*](#tf4-1){ref-type="table-fn"}      0.81[\*\*](#tf4-1){ref-type="table-fn"}     1.1[\*\*](#tf4-1){ref-type="table-fn"}      1.6[\*\*](#tf4-1){ref-type="table-fn"}       2.2                                         --                                         1.9[\*\*](#tf4-1){ref-type="table-fn"}      1.2[\*\*](#tf4-1){ref-type="table-fn"}      0.99[\*\*](#tf4-1){ref-type="table-fn"}     1.4                                        0.37[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.7; 0.93)          (0.57; 1.0)                                  (0.9; 1.4)                                  (1.5; 1.7)                                  (--0.64; 3.8)                                                                            (0.99; 2.7)                                (1.1; 1.3)                                  (0.85; 1.1)                                 (0.18; 2.6)                                 (0.34; 0.4)                                
  META                  Coefficient          3.3[\*\*](#tf4-1){ref-type="table-fn"}       3.0[\*\*](#tf4-1){ref-type="table-fn"}      3.4[\*\*](#tf4-1){ref-type="table-fn"}      3.7[\*\*](#tf4-1){ref-type="table-fn"}       --                                          --                                         3.1[\*\*](#tf4-1){ref-type="table-fn"}      3.7[\*\*](#tf4-1){ref-type="table-fn"}      2.7[\*\*](#tf4-1){ref-type="table-fn"}      2.5[\*\*](#tf4-1){ref-type="table-fn"}     2.5[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (3.2; 3.3)           (2.8; 3.3)                                   (3.2; 3.6)                                  (3.6; 3.8)                                                                                                                           (2.4; 3.9)                                 (3.6; 3.7)                                  (2.6; 2.8)                                  (1.6; 3.4)                                  (2.4; 2.5)                                 
  NEU                   Coefficient          0.43[\*\*](#tf4-1){ref-type="table-fn"}      0.79[\*\*](#tf4-1){ref-type="table-fn"}     0.44[\*\*](#tf4-1){ref-type="table-fn"}     0.57[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         0.58[\*\*](#tf4-1){ref-type="table-fn"}     0.41[\*\*](#tf4-1){ref-type="table-fn"}     0.82[\*\*](#tf4-1){ref-type="table-fn"}     0.64[\*\*](#tf4-1){ref-type="table-fn"}    0.38[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.38; 0.48)         (0.69; 0.90)                                 (0.32; 0.57)                                (0.51; 0.62)                                                                                                                         (0.29; 0.85)                               (0.36; 0.46)                                (0.77; 0.86)                                (0.30; 0.96)                                (0.34; 0.42)                               
  OBES                  Coefficient          --0.27[\*\*](#tf4-1){ref-type="table-fn"}    --                                          --0.56[\*\*](#tf4-1){ref-type="table-fn"}   --0.17[\*\*](#tf4-1){ref-type="table-fn"}    --                                          --                                         --                                          --0.69[\*\*](#tf4-1){ref-type="table-fn"}   --1.0[\*\*](#tf4-1){ref-type="table-fn"}    --                                         --0.31[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (--0.36; --0.19)                                                  (--0.81; --0.33)                            (--0.27; --0.078)                                                                                                                                                               (--0.83; --0.56)                            (--1.2; --0.83)                                                                         (--0.38; --0.25)                           
  PARA                  Coefficient          0.67[\*\*](#tf4-1){ref-type="table-fn"}      1.2[\*\*](#tf4-1){ref-type="table-fn"}      1.2[\*\*](#tf4-1){ref-type="table-fn"}      0.89[\*\*](#tf4-1){ref-type="table-fn"}      3.4[\*](#tf4-1){ref-type="table-fn"}        6.9[\*\*](#tf4-1){ref-type="table-fn"}     1.5[\*\*](#tf4-1){ref-type="table-fn"}      0.84[\*\*](#tf4-1){ref-type="table-fn"}     0.7[\*\*](#tf4-1){ref-type="table-fn"}      --                                         0.72[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.53; 0.80)         (0.99; 1.4)                                  (0.96; 1.4)                                 (0.76; 1.0)                                 (0.47; 4.9)                                  (3.9; 8.8)                                  (1.0; 1.9)                                 (0.70; 0.98)                                (0.56; 0.85)                                                                            (0.62; 0.82)                               
  PCD                   Coefficient          0.63[\*\*](#tf4-1){ref-type="table-fn"}      0.51[\*\*](#tf4-1){ref-type="table-fn"}     1.2[\*\*](#tf4-1){ref-type="table-fn"}      0.61[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         1.4[\*\*](#tf4-1){ref-type="table-fn"}      0.64[\*\*](#tf4-1){ref-type="table-fn"}     0.58[\*\*](#tf4-1){ref-type="table-fn"}     --                                         0.54[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.51; 0.73)         (0.23; 0.77)                                 (0.97; 1.4)                                 (0.49; 0.73)                                                                                                                         (1; 1.7)                                   (0.53; 0.74)                                (0.43; 0.72)                                                                            (0.48; 0.6)                                
  PSYCH                 Coefficient          0.37[\*\*](#tf4-1){ref-type="table-fn"}      0.61[\*\*](#tf4-1){ref-type="table-fn"}     0.51[\*](#tf4-1){ref-type="table-fn"}       0.77[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         1.1[\*](#tf4-1){ref-type="table-fn"}        --0.19[\*](#tf4-1){ref-type="table-fn"}     0.39[\*\*](#tf4-1){ref-type="table-fn"}     --                                         --
  95% CI                (0.26; 0.47)         (0.37; 0.83)                                 (0.17; 0.82)                                (0.66; 0.89)                                                                                                                         (0.24; 1.7)                                (--0.33; --0.059)                           (0.28; 0.49)                                                                                                                       
  PUD                   Coefficient          --                                           --                                          --0.63[\*](#tf4-1){ref-type="table-fn"}     0.41[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         --                                          --0.32[\*\*](#tf4-1){ref-type="table-fn"}   --1.6[\*\*](#tf4-1){ref-type="table-fn"}    --                                         0.2[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                                                                                  (--1.1; --0.19)                             (0.26; 0.56)                                                                                                                                                                    (--0.48; --0.17)                            (--1.9; --1.4)                                                                          (0.13; 0.27)                               
  PVD                   Coefficient          0.33[\*\*](#tf4-1){ref-type="table-fn"}      0.68[\*\*](#tf4-1){ref-type="table-fn"}     0.49[\*\*](#tf4-1){ref-type="table-fn"}     0.55[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         0.61[\*\*](#tf4-1){ref-type="table-fn"}     0.35[\*\*](#tf4-1){ref-type="table-fn"}     0.33[\*\*](#tf4-1){ref-type="table-fn"}     --                                         0.22[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.29; 0.36)         (0.62; 0.74)                                 (0.40; 0.57)                                (0.52; 0.59)                                                                                                                         (0.29; 0.92)                               (0.31; 0.39)                                (0.28; 0.37)                                                                            (0.19; 0.25)                               
  RF                    Coefficient          0.69[\*\*](#tf4-1){ref-type="table-fn"}      0.63[\*\*](#tf4-1){ref-type="table-fn"}     0.83[\*\*](#tf4-1){ref-type="table-fn"}     --                                           3.7[\*\*](#tf4-1){ref-type="table-fn"}      --                                         1[\*\*](#tf4-1){ref-type="table-fn"}        0.47[\*\*](#tf4-1){ref-type="table-fn"}     0.46[\*\*](#tf4-1){ref-type="table-fn"}     --                                         0.33[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (0.65; 0.73)         (0.54; 0.73)                                 (0.73; 0.92)                                                                            (2.8; 4.4)                                                                               (0.79; 1.2)                                (0.42; 0.52)                                (0.40; 0.51)                                                                            (0.30; 0.37)                               
  RHEU                  Coefficient          --0.12[\*](#tf4-1){ref-type="table-fn"}      --                                          --                                          0.16[\*\*](#tf4-1){ref-type="table-fn"}      --                                          --                                         --                                          --0.48[\*\*](#tf4-1){ref-type="table-fn"}   --0.29[\*\*](#tf4-1){ref-type="table-fn"}   --                                         --
  95% CI                (--0.19; --0.047)                                                                                             (0.084; 0.24)                                                                                                                                                                   (--0.58; --0.38)                            (--0.39; --0.19)                                                                                                                   
  VD                    Coefficient          --                                           --                                          --                                          --                                           --                                          --                                         0.26                                        --                                          --                                          --                                         --
  95% CI                                                                                                                                                                                                                                                                   (0.0032; 0.51)                                                                                                                                                                                                            
  WL                    Coefficient          1.6[\*\*](#tf4-1){ref-type="table-fn"}       2.4[\*\*](#tf4-1){ref-type="table-fn"}      1.3[\*\*](#tf4-1){ref-type="table-fn"}      2.1[\*\*](#tf4-1){ref-type="table-fn"}       --                                          --                                         1.5[\*\*](#tf4-1){ref-type="table-fn"}      1.7[\*\*](#tf4-1){ref-type="table-fn"}      1.3[\*\*](#tf4-1){ref-type="table-fn"}      --                                         0.94[\*\*](#tf4-1){ref-type="table-fn"}
  95% CI                (1.5; 1.6)           (2.2; 2.6)                                   (1..0; 1.6)                                 (2; 2.2)                                                                                                                             (0.86; 2.0)                                (1.6; 1.8)                                  (1.2; 1.5)                                                                              (0.88; 0.99)                               

The mark "--" in the table denotes variables that were dropped either during stepwise selection or due to their statistical insignificance (p \> 5%). Asterisks next to coefficient values denote the significance levels: one asterisk (\*): 0.1% ≤ p \< 1%; two asterisks (\*\*): p \< 0.1%.

###### 

C-statistics and number of significant variables for each model

  Rank   Model           AUC     Number of included comorbidities   Rank   Model          AUC     Number of included comorbidities
  ------ --------------- ------- ---------------------------------- ------ -------------- ------- ----------------------------------
  1      Chapter I       0.931   25                                 12     Chapter XI     0.842   27
  2      Chapter XIX     0.910   29                                 13     Chapter XX     0.839   11
  3      Chapter XIV     0.907   28                                 14     Chapter V      0.805   24
  4      Chapter XII     0.905   25                                 15     Chapter XXI    0.795   26
  5      Chapter X       0.901   27                                 16     Chapter XVII   0.781   18
  6      Chapter XVIII   0.892   28                                 17     Chapter VII    0.766   25
  7      Chapter VIII    0.884   17                                 18     Chapter IX     0.761   23
  8      Chapter IV      0.883   22                                 19     Chapter II     0.716   28
  9      Chapter III     0.861   24                                 20     Chapter XVI    0.713   4
  10     Chapter VI      0.846   23                                 21     Chapter XV     0.681   9
  11     Chapter XIII    0.844   27                                                               

Approach comparison {#sec3.3}
-------------------

[Table IV](#t0004){ref-type="table"} presents the quality of each Homogeneous Group model. There were several models with very good performance (rank 1 to 9) and as many with quite good performance (rank 10 to 18). The low predictive power of the last 3 models requires some explanation, which has been covered in the discussion section. Having compared the AUC of the Heterogeneous Group model to homogeneous ones, 13 models of subgroups yielded a C-statistic value higher than the Heterogeneous Group model (AUC \> 0.81). It is important to understand that although some Homogeneous Group models had an AUC below 0.81, they were still better classifiers than the Heterogeneous Group model for particular hospitalisations.

Discussion {#sec4}
==========

Homogeneous group approach {#sec4.1}
--------------------------

Thanks to the introduction of Homogeneous Groups, we were able to determine the difference in baseline risk between the groups. We see that the effects of comorbidities differ between groups, which supports the thesis that a division of the population is needed to obtain a good classifier.

It is worth noting that using the Homogeneous Group approach did not produce separate results. All records could be put on a single Comorbidity Index scale with one, clear, group-independent interpretation. Moreover, the CI produced a measurement that assumes only information about the demography of the patients and the diseases they suffer from, excluding the number of admissions and disease duration.

Lastly, using this methodology, we have singled out fields of medicine in which comorbidity is not applicable in such a simple approach and those in which it is very accurate.

Administrative data approach {#sec4.2}
----------------------------

Our models required only the admission data and 1-year prior medical history for each hospitalisation. This methodology made it easy to create and evaluate them on big datasets which integrate records from different hospitals.

Our study population was many times bigger than in any preceding study of comorbidity. We have retrieved records from many hospitals with a variety of specialisations. Thanks to that, our results were more general, because they are not affected by the standards of treatment in any particular hospital or by selection bias.

Low performance homogeneous groups {#sec4.3}
----------------------------------

This section explains the poor estimation power and gives suggestions on enhancing the approach to comorbidity for 3 models with the lowest C-statistics: Chapter XV -- Pregnancy, childbirth and the puerperium, Chapter XVI -- Certain conditions originating in the perinatal period, and Chapter II -- Neoplasms.

Having analysed the results of Chapter XV -- Pregnancy, childbirth and the puerperium, it was found that the training set for this group consisted of 666 100 hospitalisations, out of which only 166 were cases of 1-year mortality. Therefore, the number of positive observations was not enough to identify a well-fitted model. Perhaps another outcome variable should be defined in order to employ comorbidity for this group.

In the case of Chapter XVI -- Certain conditions originating in the perinatal period, the mortality rate in this group was higher than in the case of Chapter XV, but still low. Moreover, the number of hospitalisations was lower -- and there were only 69 cases of 1-year mortality. There is another reason why comorbidity could not meet the requirements of this subject. This group consists almost exclusively of new-born children with no diseases (99%), so there was no distinction between the records. This group cannot be analysed through comorbidity at all.

The Chapter II -- Neoplasms group has neither of the aforementioned problems: this group displays both high diversity in terms of comorbidity and high mortality. The treatment of neoplasms is often a complex path with several rehospitalisations. To build a model for predicting deaths of oncological patients, one would need to put much more thought into the analysis of a patient's medical history by adding variables denoting the number of admissions in respect of a HG that could differentiate the observations Moreover, this group was not very homogeneous (e.g. it consists of both malignant and non-malignant neoplasms) and further division is advised.

Negative effects of some comorbidities {#sec4.4}
--------------------------------------

Some comorbidities have been found to have a negative impact on mortality (in at least a few HGs), namely: depression, hypertension, hypothyroidism, obesity, peptic ulcer disease, and blood loss anaemia. The same effects were identified in \[[@cit0006]\] and attributed to administrative data unreliability, especially in reporting diagnoses of low importance in seriously ill patients.

Comparison to other studies {#sec4.5}
---------------------------

The results based our models performed as well as or better than other comorbidity-only methods for predicting patient mortality \[[@cit0008], [@cit0011]--[@cit0013]\]. So far, the best performing comorbidity-based risk adjustment models have been reported by Escobar *et al.* \[[@cit0009]\]. However, their explanatory variables included laboratory results which are not always easy to obtain, and not all patients have the same pre-admission tests.

A major limitation of this study was the reliance on administrative data, which was not recorded for research as much as it was for reimbursement. Its quality depended on the coding procedures, gaps in clinical information and the expenditure context \[[@cit0014]--[@cit0016]\], so it might not be complete. Some changes in grouping related to coding procedures specific to Polish healthcare could be applied.

The second limitation was insufficient homogeneity of considered groups. Most of them include both urgent care hospitalisations and long the lasting treatment. In our partition, we did not consider severity of a disease, which widely varies within each group. Further splitting of groups should improve the predictive power of models.

The third limitation is the poor performance of models in a few groups. Our approach did not produce a well-performing comorbidity measure for patients treated for neoplasms, during pregnancy and in the perinatal period.

In conclusion, our results support the thesis that comorbidity properly describes mortality in Homogeneous Groups of patients. In terms of C-statistics, most models performed better than the one based on the whole population. Differences in the importance of particular variables among models were observed. We have created models which were very well suited for risk adjustment -- they are the best in the literature among those which can be based solely on administrative data (e.g. not on laboratory results). In addition, all of our models can be condensed into one, uniform, single-number comorbidity scale that summarizes all of the patient's burden.
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  Chapter   Homogeneous Group                                                                                     ICD10 codes
  --------- ----------------------------------------------------------------------------------------------------- -------------
  I         Certain infectious and parasitic diseases                                                             A00--B99
  II        Neoplasms                                                                                             C00--D48
  III       Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism   D50--D89
  IV        Endocrine, nutritional and metabolic diseases                                                         E00--E90
  V         Mental and behavioural disorders                                                                      F00--F99
  VI        Diseases of the nervous system                                                                        G00--G99
  VII       Diseases of the eye and adnexa                                                                        H00--H59
  VIII      Diseases of the ear and mastoid process                                                               H60--H95
  IX        Diseases of the circulatory system                                                                    I00--I99
  X         Diseases of the respiratory system                                                                    J00--J99
  XI        Diseases of the digestive system                                                                      K00--K93
  XII       Diseases of the skin and subcutaneous tissue                                                          L00--L99
  XIII      Diseases of the musculoskeletal system and connective tissue                                          M00--M99
  XIV       Diseases of the genitourinary system                                                                  N00--N99
  XV        Pregnancy, childbirth and the puerperium                                                              O00--O99
  XVI       Certain conditions originating in the perinatal period                                                P00--P96
  XVII      Congenital malformations, deformations and chromosomal abnormalities                                  Q00--Q99
  XVIII     Symptoms, signs and abnormal clinical and laboratory findings not elsewhere classified                R00--R99
  XIX       Injury, poisoning and certain other consequences of external causes                                   S00--T98
  XX        External causes of morbidity and mortality                                                            V01--Y98
  XXI       Factors influencing health status and contact with health services                                    Z00--Z99
  XXII      Codes for special purposes                                                                            U00--U89

  No.   Comorbidity variable                               Abbre-viation   Comorbidity group (ICD10 codes)                                                                           DRG -- Chapter of ICD10
  ----- -------------------------------------------------- --------------- --------------------------------------------------------------------------------------------------------- -------------------------
  1     AIDS/HIV                                           HIV             B20, B21, B22, B24                                                                                        None
  2     Alcohol abuse                                      ALCO            F10, E52, G62.1, I42.6, K29.2, K70.0, K70.3, K70.9, T51, Z50.2, Z71.4, Z72.1                              Chapter V
  3     Blood loss anaemia                                 BLA             D50.0                                                                                                     Chapter III
  4     Cardiac arrhythmias                                CA              I44.1, I44.2, I44.3, I45.6, I45.9, I47-I49, R00.0, R00.1, R00.8, T82.1, Z45.0, Z95.0                      Chapter IX
  5     Chronic pulmonary disease                          COPD            I27.8, I27.9, J40-J47, J60-J67, J68.4, J70.1, J70.3                                                       Chapter X
  6     Coagulopathy                                       COAG            D65, D66, D67, D68, D69.1, D69.3, D69.4, D69.5, D69.6                                                     Chapter III
  7     Congestive heart failure                           CHF             I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5, I42.6, I42.7, I42.8, I42.9, I43, I50, P29.0              Chapter IX
  8     Deficiency anaemia                                 DA              D50.8, D50.9, D51, D52, D53                                                                               Chapter III
  9     Depression                                         DEP             F20.4, F31.3, F31.4, F31.5, F32, F33, F34.1, F41.2, F43.2                                                 Chapter V
  10    Diabetes, complicated                              DBC             E10.2-E010.8, E11.2- E11.8, E12.2-E012.8, E13.2-E013.8, E14.2-E014.8                                      Chapter IV
  11    Diabetes, uncomplicated                            DBU             E10.0, E10.1, E10.9, E11.0, E11.1, E11.9, E12.0, E12.1, E12.9, E13.1, E13.2, E13.9, E14.0, E14.1, E14.9   Chapter IV
  12    Drug abuse                                         DRUG            F11, F12, F13, F14, F15, F16, F18, F19, Z71.5, Z72.2                                                      Chapter V
  13    Fluid and electrolyte disorders                    FED             E22.2, E86, E87                                                                                           Chapter IV
  14    Hypertension, complicated                          HTC             I11, I12, I13, I15                                                                                        Chapter IX
  15    Hypertension, uncomplicated                        HTU             I10                                                                                                       Chapter IX
  16    Hypothyroidism                                     HPT             E00, E01, E02, E03, E89.0                                                                                 Chapter IV
  17    Liver disease                                      LD              B18, I85, I86.4, I98.2, K70, K71.1, K71.3-K71.5, K71.7, K72-K74, K76.0, K76.2-K76.9, Z94.4                Chapter XI
  18    Lymphoma                                           LYMP            C81, C82, C83, C84, C85, C88, C96, C90.0, C90.2                                                           Chapter II
  19    Metastatic cancer                                  META            C77, C78, C79, C80                                                                                        Chapter II
  20    Obesity                                            OBES            E66                                                                                                       Chapter IV
  21    Other neurological disorders                       NEU             G10-G13, G20-G22, G25.4, G25.5, G31.2, G31.8, G31.9, G32, G35-G37, G40, G41, G93.1, G93.4, R47.0, R56     Chapter VI
  22    Paralysis                                          PARA            G04.1, G11.4, G80.1, G80.2, G81, G82, G83.0, G83.1, G83.2, G83.3, G83.4, G83.9                            Chapter VI
  23    Peptic ulcer disease excluding bleeding            PUD             K25.7, K25.9, K26.7, K26.9, K27.7, K27.9, K28.7, K28.9                                                    Chapter XI
  24    Peripheral vascular disorders                      PVD             I70, I71, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, K95.8, Z95.9                     Chapter IX
  25    Psychoses                                          PSYCH           F20, F22, F23, F24, F25, F28, F29, F30.2, F31.2, F31.5                                                    Chapter V
  26    Pulmonary circulation disorders                    PCD             I26, I27, I28.0, I28.8, I28.9                                                                             Chapter IX
  27    Renal failure                                      RF              I12.0, I13.1, N18, N19, N25.0, Z49.0, Z49.1, Z49.2, Z94.0, Z99.2                                          Chapter XIV
  28    Rheumatoid arthritis/ collagen vascular diseases   RHEU            L94.0, L94.1, L94.3, M05, M06, M08, M12.0, M12.3, M30, M31.0-M31.3, M32-M35, M45, M46.1, M46.8, M46.9     Chapter XIII
  29    Solid tumour without metastasis                    CANCER          C00-C26, C30-C34, C37-C41, C43, C45-C58, C60-C76, C97                                                     Chapter II
  30    Valvular disease                                   VD              A52.0, I05-I08, I09.1, I09.8, I34-I39, Q23.0-Q23.3, Z95.2, Z95.3, Z95.4                                   Chapter IX
  31    Weight loss                                        WL              E40-E46, R63.4, R64                                                                                       Chapter IV
